Printer Friendly

COPLEY ANNOUNCES THE TENTATIVE APPROVAL OF NAPROXEN TABLETS USP

 CANTON, Mass., March 16 /PRNewswire/ -- Copley Pharmaceutical, Inc. (NASDAQ: CPLY) has received tentative FDA approval for Naproxen Tablets 250 mg/375 mg/500 mg, which is the generic equivalent of Naprosyn(R). Naprosyn is a registered trademark of Syntex.
 Delivery of Naproxen Tablets USP will commence on Dec. 22, 1993.
 Naprosyn sales are over $470 million. The drug is for the treatment of rheumatoid arthritis and osteoarthritis.
 Copley Pharmaceutical, Inc., a manufacturer of generic prescription and over-the-counter pharmaceuticals, went public in October 1992. The company develops and manufactures a broad range of off-patent prescription and over-the-counter pharmaceutical products. The company's product list includes a total of 87 dosage forms and strengths of 48 prescription and 14 over-the-counter drugs.
 -0- 3/16/93
 /CONTACT: Dr. Mark Hirsh, vice president of marketing of Copley Pharmaceutical, 800-325-6111 or 617-821-6111/
 (CPLY)


CO: Copley Pharmaceutical, Inc. ST: Massachusetts IN: MTC SU: PDT

DJ -- NE009 -- 6571 03/16/93 12:42 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Mar 16, 1993
Words:156
Previous Article:PROFITS FOR THE NEW ENGLAND UP 63 PERCENT
Next Article:JEAN PHILIPPE FRAGRANCES REPORTS RECORD 1992 RESULTS: SALES UP 72 PERCENT, NET INCOME UP 130 PERCENT; EPS $0.50 VS $0.27 FOR 1991
Topics:


Related Articles
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF LIDOCAINE HYDROCHLORIDE JELLY 2 PERCENT
COPLEY PHARMACEUTICAL ANNOUNCES THE APPROVAL OF GUANABENZ ACETATE TABLETS, USP
COPLEY PHARMACEUTICAL, INC. RECEIVES FDA APPROVAL FOR MEBENDAZOLE CHEWABLE TABLETS, 100 MG
COPLEY PHARMACEUTICAL, INC. BEGINS SHIPPING TWO NEW PRODUCTS
COPLEY PHARMACEUTICAL ANNOUNCES AVAILABILITY OF HYDROXYCHLOROQUINE TABLETS AND APPROVAL OF CAPTOPRIL TABLETS
FDA GRANTS COPLEY ANDA APPROVAL FOR PROCHLORPERAZINE MALEATE TABLETS
Sidmak Announces Significant Additions To Its Product Line:
FDA Approves Copley Pharmaceutical's ANDA for Procainamide HCl 1000 mg Tablets
Copley Pharmaceutical Receives ANDA Approval for Hydrocortisone Valerate Cream USP, 0.2%
Copley Pharmaceutical Receives ANDA Approval For Amiodarone Hydrochloride Tablets, 200 mg.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters